IsoPlexis Revenue and Competitors

Location

$330.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • IsoPlexis's estimated annual revenue is currently $15.1M per year.(i)
  • IsoPlexis received $13.5M in venture funding in September 2017.
  • IsoPlexis's estimated revenue per employee is $126,000
  • IsoPlexis's total funding is $330.5M.
  • IsoPlexis's current valuation is $325.3M. (January 2022)

Employee Data

  • IsoPlexis has 120 Employees.(i)
  • IsoPlexis grew their employee count by -66% last year.

IsoPlexis's People

NameTitleEmail/Phone
1
CSOReveal Email/Phone
2
VP ApplicationsReveal Email/Phone
3
SVP Sales OperationsReveal Email/Phone
4
VP FinanceReveal Email/Phone
5
Director Strategic ProjectsReveal Email/Phone
6
Global Director, Field Applications ScientistsReveal Email/Phone
7
Associate Director Digital MarketingReveal Email/Phone
8
Supply Chain ManagerReveal Email/Phone
9
Senior Project ManagerReveal Email/Phone
10
FAS Manager, AcademicsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M10%N/AN/A
#2
$3.3M21-25%N/AN/A
#3
$9.8M81-10%N/AN/A
#4
$1.7M11450%N/AN/A
#5
$20.3M131-23%N/AN/A
#6
$5.4M35-22%N/AN/A
#7
$2M1344%N/AN/A
#8
$2.8M1820%N/AN/A
#9
$0.3M40%N/AN/A
#10
$3.6M23-12%N/AN/A
Add Company

What Is IsoPlexis?

IsoPlexis, a venture-backed Yale-spinout company, is developing a diagnostic platform to accelerate immunology research and therapeutic development. In particular, we are developing critical solutions for the implementation of new therapeutic technologies. We are a multidisciplinary team of engineers, scientists, and software developers who thrive on scientific discovery and the development of life-changing therapeutic platforms.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$330.5M

Total Funding

120

Number of Employees

$15.1M

Revenue (est)

-66%

Employee Growth %

$325.3M

Valuation

N/A

Accelerator

IsoPlexis News

2022-04-13 - IsoPlexis Reports Preliminary First Quarter 2022 Revenue ...

BRANFORD, Conn., April 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), the Superhuman Cell Company,...

2022-04-13 - IsoPlexis Preliminary Q1 Revenues Rise up to 52 Percent ...

IsoPlexis noted that it sold 25 single-cell analysis instruments during the first quarter, bringing the total number of instruments placed to...

2022-04-06 - IsoPlexis to Present First-of-Its-Kind Data on Simultaneous ...

IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022.

2021-11-10 - IsoPlexis Reports Third Quarter 2021 Financial Results

BRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Revenue of $4.2 million for the third quarter of 2021, an increase of ...

2021-10-12 - IsoPlexis : Announces Closing of Public Offering

BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds fro ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$44.8M15110%N/A
#2
$61.7M170N/AN/A
#3
$52M1757%N/A
#4
$34.3M20816%N/A
#5
$34.1M21428%N/A

IsoPlexis Funding

DateAmountRoundLead InvestorsReference
2014-08-12$0.3MUndisclosedConnecticut InnovationsArticle
2015-06-02$2.4MUndisclosedArticle
2017-09-26$13.5MBSpring Mountain CapitalArticle